血管内皮前駆細胞（EPC）を用いた重症虚血肢に対する再生治療
スポンサーリンク
概要
- 論文の詳細を見る
Peripheral artery disease (PAD) is mainly caused by atherosclerosis and is associated with significant morbidity and mortality. Arteriosclerosis obliterans (ASO) is the most common cause of PAD affecting the lower limbs. Additional causes of PAD are Buerger's disease and collagen diseases involving vasculitis. Currently, the standard treatment for CLI is medication, surgical or endovascular revascularization. However, such interventions can be performed in only 50% of CLI patients and the CLI-resolved ratio is only 25% one year after the initial treatment. Among the CLI patients in whom attempts at revascularization have failed, 30% lose their legs and 25% die within one year after treatment. Therefore, the development of novel therapeutic strategies is urgently needed to improve the poor prognosis of CLI patients. Bone marrow-derived endothelial progenitor cells (EPCs) have been identified as a potential new therapeutic option for neovascularization. The preclinical findings have encouraged clinical researchers to explore the safety, feasibility and efficacy of cell-based therapies including unselected bone marrow-derived mononuclear cells and EPCs in patients with CLI in several small clinical trials. The results of these clinical trials revealed that cell-based therapies for no-option CLI patients are relatively safe, feasible and possibly effective. Recently, large-scale, randomized, placebo-controlled, double-blind studies are in progress to further confirm this evidence.
- 一般社団法人日本インターベンショナルラジオロジー学会の論文
一般社団法人日本インターベンショナルラジオロジー学会 | 論文
- 部分的脾動脈塞栓術Partial Splenic Embolizationにおける塞栓率予測のためのワークステーションを用いた術前CTについての解析
- いまさら聞けないＩＶＲの基本 ４．金属コイル塞栓術
- 大動脈解離による腹部分枝動脈狭窄に対してステント治療を施行した4例
- 頸動脈ステント留置術の基本
- 腎癌に対するラジオ波凝固治療